牛牛AI助手已提取核心信息
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of iBio Inc's common stock. The filing, dated February 13, 2024, shows that The Vanguard Group now beneficially owns 8,439 shares of iBio Inc, which represents 0.23% of the company's class of common stock. This position is a result of shared dispositive power over 152 shares and sole dispositive power over 8,287 shares. The Vanguard Group, based in Pennsylvania, has declared that the acquisition of these shares is for investment purposes and not with the intent to change or influence the control of iBio Inc. The filing confirms that The Vanguard Group's clients have the right to receive dividends or proceeds from the sale of these securities, and no single client's interest exceeds 5% of the class.
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of iBio Inc's common stock. The filing, dated February 13, 2024, shows that The Vanguard Group now beneficially owns 8,439 shares of iBio Inc, which represents 0.23% of the company's class of common stock. This position is a result of shared dispositive power over 152 shares and sole dispositive power over 8,287 shares. The Vanguard Group, based in Pennsylvania, has declared that the acquisition of these shares is for investment purposes and not with the intent to change or influence the control of iBio Inc. The filing confirms that The Vanguard Group's clients have the right to receive dividends or proceeds from the sale of these securities, and no single client's interest exceeds 5% of the class.
2023年12月29日，Vanguard集团向美国证券交易委员会提交了经修订的附表13G/A，表明其持有的iBio Inc普通股发生了变化。这份日期为2024年2月13日的文件显示，先锋集团现在实益拥有iBio Inc的8,439股股份，占该公司普通股类别的0.23％。该地位是对152股股票的共同处置权和对8,287股的唯一处置权的结果。总部位于宾夕法尼亚州的Vanguard Group宣布，收购这些股票是出于投资目的，无意改变或影响iBio Inc.的控制权。该文件证实，Vanguard Group的客户有权获得出售这些证券的股息或收益，任何一个客户的利息都不超过该类别的5％。
2023年12月29日，Vanguard集团向美国证券交易委员会提交了经修订的附表13G/A，表明其持有的iBio Inc普通股发生了变化。这份日期为2024年2月13日的文件显示，先锋集团现在实益拥有iBio Inc的8,439股股份，占该公司普通股类别的0.23％。该地位是对152股股票的共同处置权和对8,287股的唯一处置权的结果。总部位于宾夕法尼亚州的Vanguard Group宣布，收购这些股票是出于投资目的，无意改变或影响iBio Inc.的控制权。该文件证实，Vanguard Group的客户有权获得出售这些证券的股息或收益，任何一个客户的利息都不超过该类别的5％。
有用
没用